摘要
SET(SE易位,SET)是在各种人体组织中广泛表达的进化保守基因,特别是在性腺和神经系统中。作为多任务蛋白质,SET涉及必需的细胞过程,例如组蛋白修饰,染色质重塑,DNA修复,基因转录和雄激素合成。最近的研究表明,SET在乳腺癌,卵巢癌和各种其他恶性肿瘤中过表达。 SET表达水平与卵巢癌患者生存率和SET介导的雄激素合成活化之间的强相关性强烈表明,该因子可能在妇科癌症中起重要作用。在这里,我们总结了关于SET在肿瘤发生和癌症进展中的病理学意义的数据。我们分析了如何通过PP2A依赖和不依赖于PP2A途径的SET可以调节不同的细胞功能。还讨论了这些途径之间的潜在相互作用以及对SET的致癌活性的未来研究。
关键词: SET,PP2A,I2PP2A,INHAT,妇科癌症,类固醇激素,组蛋白伴侣。
Current Drug Targets
Title:Oncogenic Role of SET/I2PP2A for Gynecologic Cancers
Volume: 18 Issue: 10
关键词: SET,PP2A,I2PP2A,INHAT,妇科癌症,类固醇激素,组蛋白伴侣。
摘要: SET (SE translocation, SET) is an evolutionarily conserved gene broadly expressed in various human tissues, especially in the gonadal and neural system. As a multitasking protein, SET is involved in essential cell processes such as histone modification, chromatin remodeling, DNA repair, gene transcription, and androgen synthesis. Recent studies showed that SET is overexpressed in breast cancers, ovary cancers and a variety of other malignancies. The strong correlation between SET expression levels and survival of ovarian cancer patients, and SET-mediated activation of androgen synthesis, strongly indicated that this factor may play a significant role in gynecologic cancers. Here, we summarized data pertaining to the pathological implications of SET in tumorigenesis and cancer progression. We analyzed how SET, through the PP2A-dependent and PP2A-independent pathways, may regulate different cell functions. Potential interactions among these pathways and future studies on SET’s oncogenic activities are also discussed.
Export Options
About this article
Cite this article as:
Oncogenic Role of SET/I2PP2A for Gynecologic Cancers, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450118666170328114506
DOI https://dx.doi.org/10.2174/1389450118666170328114506 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
<i>Prunella vulgaris</i> L: Critical Pharmacological, Expository Traditional
Uses and Extensive Phytochemistry: A Review
Current Drug Discovery Technologies Synergistic Effect of the Combination of Novel Suberoylanilide Hydroxamic Acid Derivatives with Cisplatin on Anti-proliferation of Human Cancer Cells
Medicinal Chemistry Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy
Current Cancer Drug Targets Better Targeting Melanoma: Options Beyond Surgery and Conventional Chemotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design Tumoural Expression of Connective Tissue Growth Factor (CTGF) Impacts on Survival in Patients Diagnosed with Hepatocellular Carcinoma (HCC)
Current Cancer Drug Targets Relevance of the Deletion Polymorphisms of the Glutathione S-Transferases GSTT1 and GSTM1 in Pharmacology and Toxicology
Current Drug Metabolism Tea and Health: Studies in Humans
Current Pharmaceutical Design Epidemiology, Clinical Presentation and Treatment of Mucosal Melanoma
Clinical Cancer Drugs Metallothioneins and Cancer
Current Protein & Peptide Science Molecular Classification of Breast Carcinoma In Situ
Current Genomics Docking Studies and Antiproliferative Activities of 6-(3-aryl-2-propenoyl)-2(3H)- benzoxazolone Derivatives as Novel Inhibitors of Phosphatidylinositol 3-Kinase (PI3Kα)
Anti-Cancer Agents in Medicinal Chemistry Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Recent Patents on Anti-Cancer Drug Discovery A Current Review on Drug Loaded Nanofibers: Interesting and Valuable Platform for Skin Cancer Treatment
Pharmaceutical Nanotechnology Epigenetics and Periodontal Disease: Hope to Tame the Untameable
Current Gene Therapy Risk Factors for Node Affectation and Recurrence in Endometrial Cancer
Current Women`s Health Reviews Diagnostic Devices for Circulating Biomarkers Detection and Quantification
Current Medicinal Chemistry Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Editorial [ Hot topic:Updates on Therapeutic Approaches to Inflammatory Skin Diseases: From Molecular Targets to Drug Development. Part I (Guest Editors: L. Korkina & S. Pastore) ]
Current Drug Metabolism Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway
Current Cancer Therapy Reviews